TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18161668

Group type: EXPERIMENTAL
Intervention: Primary thromboprophylaxis (PTP) with unfractionated heparin (5‐10 units/kg/hr) infusion postoperatively, followed by subcutaneous low molecular weight heparin (LMWH) at prophylactic dose (0.5 mg/kg/d) and therapeutic dose (1 mg/kg/d) based on thrombosis predisposition.
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-treatment group (Historical group) with 12 AVFs that did not receive thromboprophylaxis.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aspirin group (Historical group) with 5 AVFs receiving 81 mg aspirin/day.
Number of subjects: 21

Group type: COMPARATOR
Intervention: LMWH group (Historical group) with 2 AVFs receiving LMWH.
Number of subjects: 21
Study: 16309093

Group type: EXPERIMENTAL
Intervention: Acupuncture-massage comprehensive program
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 12530749

Group type: EXPERIMENTAL
Intervention: Aural lists
Number of subjects: 99

Group type: COMPARATOR
Intervention: Visually presented words
Number of subjects: 99

Group type: COMPARATOR
Intervention: Pictorial images
Number of subjects: 99
Study: 10984382

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with a standardized latex extract
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8636753

Group type: EXPERIMENTAL
Intervention: Toremifene (60 mg orally per day for 3 years)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg orally per day for 3 years)
Number of subjects: 49
Study: 1592840

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 3863624

Group type: EXPERIMENTAL
Intervention: PGE2 gel (0.5 mg dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31504908

Group type: EXPERIMENTAL
Intervention: Climatized environment (26°C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non‐climatized environment (29°C)
Number of subjects: 300
Study: 29701621

Group type: EXPERIMENTAL
Intervention: VYC-17.5L
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control HA dermal filler
Number of subjects: 123
Study: 27295427

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 25315644

Group type: EXPERIMENTAL
Intervention: Your Path to Transplant (YPT) intervention
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual Care Control Education (UC)
Number of subjects: 900
Study: 22341081

Group type: EXPERIMENTAL
Intervention: PathFile (P)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stainless-steel K-file (K)
Number of subjects: 16
Study: 21046498

Group type: EXPERIMENTAL
Intervention: Conventional thyroidectomy (Group 1)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Flapless conventional thyroidectomy (Group 2)
Number of subjects: 142
Study: 17335011

Group type: EXPERIMENTAL
Intervention: Internet questionnaire
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Written questionnaire
Number of subjects: 1071
Study: 15910726

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy (PG)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Pancreatojejunostomy (PJ)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Reoperations and/or postoperative interventional radiology drainages
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 149
Study: 15618687

Group type: EXPERIMENTAL
Intervention: Cefdinir 200 mg alone (Study 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefdinir 200 mg and calcium polycarbophil 1200 mg (Study 2)
Number of subjects: 0
Study: 10443862

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM) with DETERMINE Checklist scores of four or higher
Number of subjects: 251

Group type: COMPARATOR
Intervention: Geriatric evaluation and management (GEM) with DETERMINE Checklist scores lower than four
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: DETERMINE Checklist scores
Number of subjects: 251
Study: 8847680

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2259185

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg orally twice a day for 14 days and an additional 400 mg intravenously during hemodialysis)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (oral treatment)
Number of subjects: 8
Study: 31802692

Group type: EXPERIMENTAL
Intervention: Probiotics combined with early enteral nutrition
Number of subjects: 76

Group type: COMPARATOR
Intervention: Enteral nutrition alone
Number of subjects: 76
Study: 30372127

Group type: EXPERIMENTAL
Intervention: Stainless Steel (SS) bone screws
Number of subjects: 386

Group type: COMPARATOR
Intervention: Titanium Alloy (TiA) bone screws
Number of subjects: 386
Study: 27933399

Group type: EXPERIMENTAL
Intervention: Nurse-guided clinical decision support system for rehydration treatment
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care by attending physician
Number of subjects: 222
Study: 26324406

Group type: EXPERIMENTAL
Intervention: Low-PA/high-oleic-acid (HOA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-PA (HPA) diet
Number of subjects: 0
Study: 23515275

Group type: COMPARATOR
Intervention: Medical therapy alone (MED)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: CABG surgery (in patients assigned to MED who underwent CABG)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: CABG surgery (per-protocol)
Number of subjects: 1212

Group type: COMPARATOR
Intervention: CABG to MED crossover population
Number of subjects: 1212
Study: 22256652

Group type: EXPERIMENTAL
Intervention: Infantile Tuina treatment (tonifying Pijing, clarifying Dachangjing, Tuina on Lanmen, Qi, Fu Shangqijiegu, Guiwei, Zusanli (ST 36), Banmen, Sanguan)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral administration of Smecta
Number of subjects: 240
Study: 19791830

Group type: EXPERIMENTAL
Intervention: Lapatinib combined with capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study: 16749416

Group type: EXPERIMENTAL
Intervention: Forskolin at 10 mg/day orally for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium cromoglycate with two inhalations every 8 hours for 6 months
Number of subjects: 40
Study: 15687789

Group type: EXPERIMENTAL
Intervention: Home visiting discharge education
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine hospital discharge education
Number of subjects: 35
Study: 11734518

Group type: EXPERIMENTAL
Intervention: Posterior sub-Tenon's anaesthetic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthetic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9143084

Group type: EXPERIMENTAL
Intervention: Spinal cord injury (injured for less than 1 year)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spinal cord injury (injured for more than 1 year)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Paraplegic and quadriplegic patients (40-59 and 60+ years of age)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Age-matched able-bodied controls
Number of subjects: 3
Study: 8187990

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (209 sessions)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 116
Study: 3539306

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (no TS)
Number of subjects: 126
Study: 31725105

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Patient-choice diet (control) for 12 weeks
Number of subjects: 17
Study: 29807694

Group type: EXPERIMENTAL
Intervention: GA-GYN score (derived from a predictive model utilizing components of an abbreviated geriatric assessment)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: GA-GYN score (in subgroup analysis)
Number of subjects: 189
Study: 27110224

Group type: EXPERIMENTAL
Intervention: 7.5% CHO ingestion (CHOI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15% CHO mouth rinse (CHOR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 9
Study: 26529070

Group type: EXPERIMENTAL
Intervention: Flublok
Number of subjects: 2640

Group type: COMPARATOR
Intervention: AFLURIA
Number of subjects: 2640
Study: 22538270

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg b.i.d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Brivaracetam (150 mg) alone
Number of subjects: 26
Study: 19969437

Group type: EXPERIMENTAL
Intervention: Pimozide formulation 1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pimozide formulation 2
Number of subjects: 32
Study: 18768019

Group type: EXPERIMENTAL
Intervention: Sensodyne Sensitive (SENS)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral-B Sensitive Advantage (OBSA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: All three brushes (SENS, OBSA, ADA)
Number of subjects: 76
Study: 16902978

Group type: EXPERIMENTAL
Intervention: Temporal correlation (TC) mapping method during dynamic contrast-enhanced (DCE) MRI
Number of subjects: 30
Study: 12947368

Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10373752

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 10
Study: 8803371

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 79
Study: 1804650

Group type: EXPERIMENTAL
Intervention: AS-4370 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AS-4370 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AS-4370 2.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6135506

Group type: EXPERIMENTAL
Intervention: Continue beta-blocker treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Stop beta-blocker treatment
Number of subjects: 56
Study: 31535566

Group type: EXPERIMENTAL
Intervention: Framingham cardiovascular disease (CVD) risk equation
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: UKPDS coronary heart disease (CHD) risk equation
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: UKPDS Fatal CHD risk equation
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: UKPDS Stroke risk equation
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: UKPDS Fatal Stroke risk equation
Number of subjects: 660
Study: 30072044

Group type: EXPERIMENTAL
Intervention: Barrier-belief counseling intervention (BBCI)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Standardized lifestyle group intervention (SLI)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Non-treated hanging control group
Number of subjects: 245
Study: 27176122

Group type: EXPERIMENTAL
Intervention: Propofol sedation by anesthesiologists (ANES)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Propofol sedation by gastroenterologist-led teams (GLT)
Number of subjects: 272

Group type: COMPARATOR
Intervention: No sedation (PLCB)
Number of subjects: 272
Study: 25365188

Group type: EXPERIMENTAL
Intervention: Multiple doses of 50 mg·kg(‐1) silybin for 15 consecutive days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg·kg(‐1) silybin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no silybin)
Number of subjects: 18
Study: 22525777

Group type: EXPERIMENTAL
Intervention: Trunk Stabilization (TS) exercises
Number of subjects: 37

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 37
Study: 20372991

Group type: EXPERIMENTAL
Intervention: Azithromycin capsules (fed state)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin capsules (fasted state)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin tablets (fed state)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azithromycin tablets (fasted state)
Number of subjects: 0
Study: 17963629

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ 80/12.5 mg once daily
Number of subjects: 864

Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily
Number of subjects: 864
Study: 16308411

Group type: EXPERIMENTAL
Intervention: Wet wrap bandages
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional topically applied ointments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study: 12824660

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 431

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 431
Study: 10482997

Group type: EXPERIMENTAL
Intervention: Group I (CD5+ type)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Group II (CD5- CD10+ type)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Group III (CD5- CD10- type)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall DLBL cases
Number of subjects: 63
Study: 8942454

Group type: EXPERIMENTAL
Intervention: Clozapine at low serum level range (50-150 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clozapine at medium serum level range (200-300 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clozapine at high serum level range (350-450 ng/ml)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 56
Study: 2017535

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.5 mg
Number of subjects: 55
Study: 6637819

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) 50 to 200 micrograms/kg/hour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine 0.15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Furosemide 1 mg/kg after ISDN
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Furosemide 1 mg/kg after hydralazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Furosemide in both groups
Number of subjects: 20
Study: 30576336

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI) score assessment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bifidobacterium count
Number of subjects: 240
Study: 28103948

Group type: EXPERIMENTAL
Intervention: Patient-tailored, pharmacist-led intervention programme consisting of a structured interview at the pharmacy to identify barriers to adherence and counsel patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-tailored, pharmacist-led intervention programme
Number of subjects: 0
Study: 26335704

Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully intervention plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 24245807

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: waiting list
Number of subjects: 79
Study: 21148119

Group type: EXPERIMENTAL
Intervention: Topiramate 64 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Topiramate 384 mg/day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 18308157

Group type: EXPERIMENTAL
Intervention: Distal protection during PCI (n = 312)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Conventional treatment without distal protection (n = 314)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 626

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 626
Study: 17165292

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD) in 3 configurations: (1) without retention pin, (2) with retention pin < 40%, (3) with retention pin > 75%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Maxillary Occlusal Splint (MOS)
Number of subjects: 13
Study: 14592916

Group type: EXPERIMENTAL
Intervention: Extended transsternal thymectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11259988

Group type: EXPERIMENTAL
Intervention: Budesonide (256 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg)
Number of subjects: 24
Study: 9526578

Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) at a dose of 200 mg per os every day for 5 years
Number of subjects: 2972
Study: 8345067

Group type: COMPARATOR
Intervention: Short protocol (buserelin 1 mg/day intranasally from cycle day 1 and HMG 2 ampoules/day from day 3 until HCG administration)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Long protocol (buserelin 1 mg/day intranasally from cycle day 1 for at least 14 days, then HMG 2 ampoules/day added)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 428

Group type: COMPARATOR
Intervention: Short protocol
Number of subjects: 428
Study: 3767129

Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 17

Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 17
Study: 29455894

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for MS-related fatigue, 16-week treatment.
Number of subjects: 91

Group type: COMPARATOR
Intervention: MS-nurse consultations (control group).
Number of subjects: 91
Study: 27398992

Group type: EXPERIMENTAL
Intervention: CPAP at 5 cm H2O
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O
Number of subjects: 194

Group type: COMPARATOR
Intervention: Sham CPAP (less than 1 cm H2O)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 194
Study: 24919077

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS to M1nonlesioned
Number of subjects: 10

Group type: COMPARATOR
Intervention: Anodal tDCS to M1lesioned
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 23333044

Group type: EXPERIMENTAL
Intervention: Inhalation of L-arginine (500 mg, twice daily for two weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline inhalation (control)
Number of subjects: 19
Study: 21394118

Group type: EXPERIMENTAL
Intervention: Merogel
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 260
Study: 18312884

Group type: EXPERIMENTAL
Intervention: Paper-patch myringoplasty
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fat myringoplasty
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Perichondrium myringoplasty
Number of subjects: 45
Study: 16780613

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 20
Study: 12788872

Group type: EXPERIMENTAL
Intervention: 50 mg/d AA2500 testosterone gel
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 100 mg/d AA2500 testosterone gel
Number of subjects: 406

Group type: COMPARATOR
Intervention: Testosterone patch
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 406
Study: 10819821

Group type: EXPERIMENTAL
Intervention: Misoprostol, 50 microg intravaginally every 4 hours
Number of subjects: 123

Group type: COMPARATOR
Intervention: Extra-amniotic sodium chloride infusion
Number of subjects: 123
Study: 8771664

Group type: EXPERIMENTAL
Intervention: Interferons (alpha‐2 and gamma‐interferons) administered in daily doses of 15,000‐25,000 IU/kg and 1500‐2500 IU/kg, respectively.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferons (alpha‐2 and gamma‐interferons)
Number of subjects: 0
Study: 1614182

Group type: EXPERIMENTAL
Intervention: Inhaled amiloride (10(‐3)M), twice daily for two months
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.9% saline (control), twice daily for two months
Number of subjects: 9
Study: 3886209

Group type: EXPERIMENTAL
Intervention: Moderate dose AVP infusion (25 pmol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose AVP infusion (75 pmol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AVP infusion
Number of subjects: 0
Study: 31650640

Group type: EXPERIMENTAL
Intervention: 2014 study
Number of subjects: 0
Study: 29499522

Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing (CRP POCT)
Number of subjects: 58
Study: 26971332

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 43
Study: 24708575

Group type: EXPERIMENTAL
Intervention: Bortezomib (4 × 1.3 mg/m2 over 2 weeks; 3-month interval between cycles)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 44
Study: 22595390

Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention
Number of subjects: 80
Study: 20233185

Group type: EXPERIMENTAL
Intervention: Lercanidipine (2 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Amlodipine (1 mg)
Number of subjects: 19
Study: 18567973

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 16649829

Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (healthy female volunteers)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Between-group analysis
Number of subjects: 7
Study: 12794211

Group type: EXPERIMENTAL
Intervention: Ligase chain reaction (LCR) on first void urine (FVU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cultures of urethral and cervical swabs
Number of subjects: 29